DK1963484T3 - Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf - Google Patents

Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf

Info

Publication number
DK1963484T3
DK1963484T3 DK06820577.2T DK06820577T DK1963484T3 DK 1963484 T3 DK1963484 T3 DK 1963484T3 DK 06820577 T DK06820577 T DK 06820577T DK 1963484 T3 DK1963484 T3 DK 1963484T3
Authority
DK
Denmark
Prior art keywords
applications
bacterial strains
producing raw
raw bacterial
producing
Prior art date
Application number
DK06820577.2T
Other languages
English (en)
Inventor
John Lawson Stanford
Cynthia Ann Stanford
Graham Mcintyre
Oscar Adelmo Bottasso
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Application granted granted Critical
Publication of DK1963484T3 publication Critical patent/DK1963484T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
DK06820577.2T 2005-12-21 2006-12-19 Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf DK1963484T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0526033.6A GB0526033D0 (en) 2005-12-21 2005-12-21 Method
PCT/GB2006/004780 WO2007071978A1 (en) 2005-12-21 2006-12-19 Method of producing rough strains of bacteria and uses thereof

Publications (1)

Publication Number Publication Date
DK1963484T3 true DK1963484T3 (da) 2011-09-19

Family

ID=35840894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06820577.2T DK1963484T3 (da) 2005-12-21 2006-12-19 Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf

Country Status (15)

Country Link
US (2) US8071354B2 (da)
EP (2) EP1963484B1 (da)
JP (1) JP5202330B2 (da)
CN (1) CN101384699B (da)
AT (1) ATE519838T1 (da)
AU (1) AU2006328209B2 (da)
BR (1) BRPI0620291B8 (da)
CA (1) CA2633127C (da)
DK (1) DK1963484T3 (da)
ES (1) ES2369569T3 (da)
GB (1) GB0526033D0 (da)
NZ (1) NZ568810A (da)
PL (1) PL1963484T3 (da)
SI (1) SI1963484T1 (da)
WO (1) WO2007071978A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
MX2017016931A (es) 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
US20200061130A1 (en) * 2016-02-25 2020-02-27 Thomas Julius Borody Compositions and methods of treatment of chronic infectious diseases
US20190374631A1 (en) * 2016-06-24 2019-12-12 Aptimmune Biologics, Inc. Methods of priming a sus' immune system
CN111107859B (zh) 2017-06-14 2022-04-29 4D制药研究有限公司 包含细菌菌株的组合物
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
MA54074A (fr) * 2018-11-02 2022-02-09 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3876964A1 (en) 2018-12-12 2021-09-15 4D Pharma Research Limited Compositions comprising parabacteroides bacterial strains for treating cancer
WO2021147899A1 (zh) * 2020-01-21 2021-07-29 辽宁格瑞仕特生物制药有限公司 赤红球菌细胞壁骨架在再生医学中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054055A (en) 1975-05-27 1979-05-08 Raymond Turcotte Isolation and characterization of phenotypes of mycobacteria
WO1991002562A1 (en) 1989-08-17 1991-03-07 Surgical Laser Products, Inc. Integral end structure for medical laser waveguide
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
AU9027191A (en) 1990-11-05 1992-05-26 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
AU660430B2 (en) 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
US5521300A (en) 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
DK0592894T3 (da) 1992-10-13 2001-08-06 Hoffmann La Roche Oligonukleotider afledt af SOD-familien
US6136529A (en) 1993-09-03 2000-10-24 Gen-Probe Incorporated Nucleic acid probes to Mycobacterium avium complex
US5786326A (en) 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5994346A (en) 1995-02-03 1999-11-30 Regents Of The University Of California Use of exochelins in the preservation of organs for transplant
WO1997044488A2 (en) 1996-05-22 1997-11-27 Gen-Probe Incorporated Compositions and methods for the detection of mycobacterium kansasii
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9701897D0 (en) 1997-01-30 1997-03-19 Aqua Health Europ Ltd Vaccine
US7067500B2 (en) 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
DE19911208A1 (de) 1999-03-13 2000-09-14 Walther Carl Kurt Gmbh Steckkupplung zur Verbindung von Rohrleitungen, Schläuchen oder dergleichen
GB0025694D0 (en) 2000-10-19 2000-12-06 Univ London Vaccine
EP1511753A4 (en) 2001-09-06 2005-10-12 Activbiotics Inc ANTIMICROBIAL MEDIUM AND ITS USE
US7122525B2 (en) 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
AU2002364562A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
WO2003068918A2 (en) 2002-02-11 2003-08-21 Auburn University High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
WO2003101445A1 (en) 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
WO2004022093A1 (en) * 2002-09-06 2004-03-18 University College London Whole bacterial cells as immune modulator
GB2422544B (en) 2003-11-14 2008-05-14 Ucl Biomedica Plc Immune modulator
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
EP1831518B1 (en) * 2004-12-27 2016-04-13 Federal-Mogul Powertrain, Inc. Heat shield for engine mount

Also Published As

Publication number Publication date
WO2007071978A1 (en) 2007-06-28
ES2369569T3 (es) 2011-12-02
AU2006328209A1 (en) 2007-06-28
EP2298860A2 (en) 2011-03-23
CA2633127A1 (en) 2007-06-28
JP2009520489A (ja) 2009-05-28
NZ568810A (en) 2011-09-30
US20120082699A1 (en) 2012-04-05
ES2369569T8 (es) 2012-06-26
SI1963484T1 (sl) 2012-06-29
BRPI0620291B8 (pt) 2021-05-25
BRPI0620291B1 (pt) 2020-12-15
CN101384699A (zh) 2009-03-11
US8512694B2 (en) 2013-08-20
CA2633127C (en) 2015-08-04
ATE519838T1 (de) 2011-08-15
GB0526033D0 (en) 2006-02-01
US20090304749A1 (en) 2009-12-10
CN101384699B (zh) 2012-10-10
BRPI0620291A2 (pt) 2011-11-08
EP1963484B1 (en) 2011-08-10
PL1963484T3 (pl) 2012-08-31
EP1963484A1 (en) 2008-09-03
AU2006328209B2 (en) 2012-10-11
US8071354B2 (en) 2011-12-06
JP5202330B2 (ja) 2013-06-05
EP2298860A3 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
DK1963484T3 (da) Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf
WO2009158658A3 (en) Induction of flocculation in photosynthetic organisms
DK1856257T3 (da) Fremgangsmåder under anvendelser af oligonucleotid med dobbelt specificitet og oligonucleotid med dobbelt specificitet
PH12015501581A1 (en) Method for using a bacillus subtilis strain to enhance animal health
WO2007134294A3 (en) Novel chlorella species and uses therefor
DK2016169T3 (da) Solvent-tolerante mikroorganismer og fremgangsmåder til isolering
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
MY153228A (en) Composition to treat and/ or prevent gastrointestinal infection
WO2006032724A3 (en) Novel laccase enzymes and their uses
EP1847630A4 (en) LOW-STRENGTH / HIGH-CONCENTRATION LOW-CONTAMINATED TEMPERED ELEMENT AND METHOD OF MANUFACTURING THE SAME
ZA201109086B (en) Prevention and treatment of allergic diarrhoea
DE602008000176D1 (de) Verfahren zur Umwandlung von Glukose in Aniline durch Mikroorganismen
MY149886A (en) Novel strains of lactobacillus helveticus
HK1154258A1 (en) Ammonium polyurethane and or polycarbonate compounds
ATE491335T1 (de) Bakterielles produkt marinen ursprungs, das sich zur verhinderung des durch makroalgen und wirbellose meerestiere verursachten makro- und mikro-biofouling eignet
ATE498679T1 (de) Neuer, dem wirt gegen krankheiten gerichtete eigenschaften verleihender stamm und bakterienzellzusammensetzung
WO2006071746A3 (en) Engineered dopamine neurons and uses thereof
TW200629123A (en) Mechanical input-unit for a display-unit with a pressure-sensitive surface
TNSN07090A1 (en) Novel laccase enzyme and use thereof
WO2010139408A3 (de) Flubendiamide-nützlings-kombinationen
DK2117327T3 (da) Fremgangsmåde til fremstilling af en mælk til mælkemejeri-anvendelser, mælken opnået ved denne fremgangsmåde og anvendelserne deraf
WO2008073617A3 (en) Increasing tolerance of plants to low light conditions
MY160112A (en) Use of a carbonaceous substitute for the production of yeasts
NO20075157L (no) Fremgangsmate og innretning for a isolere mikroorganismer
WO2007019616A3 (en) Modification of endophyte infection